KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xylem (XYL) EBT (2016 - 2025)

Historic EBT for Xylem (XYL) over the last 16 years, with Q3 2025 value amounting to $297.0 million.

  • Xylem's EBT rose 1040.89% to $297.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 2885.03%. This contributed to the annual value of $1.1 billion for FY2024, which is 7118.11% up from last year.
  • Xylem's EBT amounted to $297.0 million in Q3 2025, which was up 1040.89% from $299.0 million recorded in Q2 2025.
  • Xylem's EBT's 5-year high stood at $375.0 million during Q4 2024, with a 5-year trough of $17.0 million in Q3 2022.
  • In the last 5 years, Xylem's EBT had a median value of $185.0 million in 2023 and averaged $183.5 million.
  • Per our database at Business Quant, Xylem's EBT plummeted by 8721.8% in 2022 and then skyrocketed by 98823.53% in 2023.
  • Xylem's EBT (Quarter) stood at $126.0 million in 2021, then skyrocketed by 50.0% to $189.0 million in 2022, then increased by 11.11% to $210.0 million in 2023, then skyrocketed by 78.57% to $375.0 million in 2024, then fell by 20.8% to $297.0 million in 2025.
  • Its EBT stands at $297.0 million for Q3 2025, versus $299.0 million for Q2 2025 and $217.0 million for Q1 2025.